Author(s): Vineel Muppidi1, Sudeep Madisetti2, Lingaiah Jadi3, Kalicheti Prabhakar Reddy4, Madasani Anunya Reddy5
BACKGROUND Allergic rhinitis is known to be one of the most common chronic diseases in the world. In this study, we provide an overview of allergic rhinitis responding to immunostimulating agents. According to the concept that allergic rhinitis patients generally suffer from an immune deficit in order to stimulate their immune system specifically or nonspecifically, immunomodulating agents from various sources such as synthetic compounds, tissue extracts or a mixture of bacterial extracts have been used.
MATERIALS AND METHODS
The aim of the present trial is to evaluate the efficacy of the treatment with an immunostimulating agent consisting of a freeze dried bacterial lysates (Ismigen) and analyse the improvement in clinical response in allergic rhinitis patients. 50 allergic rhinitis patients were enrolled. For all patients, after 3 months of PMBL (polyvalent mechanical bacterial lysates) treatment clinical response was analysed.
A clinical improvement in subjective symptoms was observed in 43 of the 50 patients treated with bacterial lysates (85.6%). The results are as follows- 45 patients (91.8%), we noticed a decrease in symptoms of nasal blockage and 38 patients (90.4%) were relieved from rhinorrhea; purulent nasal discharge was reduced in 13 cases (81.5%), 30 patients (90.9%) had a large improvement in nasal/palate itching and 15 patients (75%) with headache were relieved.
CONCLUSION From this study, bacterial lysates have shown to have a protective effect, which induces a significant reduction of the symptoms and duration related to allergic rhinitis. No negative side effects or worsening of the symptoms have been observed with this medication.